Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 292

The DOI matches its Crossref record.

Thrombotic Stroke and Myocardial Infarction With Hormonal Contraception

Lidegaard, Øjvind, Løkkegaard, Ellen, Jensen, Aksel, Skovlund, Charlotte Wessel, Keiding, Niels·2012·Obstetrical & Gynecological Survey

Abstract

Several studies published in the past 10 years have evaluated the risk of venous thromboembolic complications with the use of newer hormonal contraceptives, but few have examined the risk of thrombotic stroke and myocardial infarction. Results of the few available studies have been conflicting. The aim of the Danish historical cohort study was to assess the risks of thrombotic stroke and myocardial infarction among women who received various types of hormonal contraception. Over a 15-year period (1995–2009), data were obtained on use of hormonal contraception, clinical end points, and potential confounders from national registries for nonpregnant women, 15 to 49 years old, who had no history of cardiovascular disease or cancer. Data on contraceptives were stratified according to estrogen dose, progestin, and route of administration. The crude incidence rate and adjusted relative risk (RR) of thrombotic events were compared in users of contraceptives and nonusers. The study cohort was composed of 1,626,158 women with 14,251,063 person-years of observation. Among this population, 3311 had a first thrombotic stroke (21.4 per 100,000 person-years), and 1725 had a first myocardial infarction (10.1 per 100,000 person-years). Relative risks for thrombotic stroke or myocardial infarction among current users of oral contraceptives at a dose of ethinyl estradiol of 30 to 40 μg, according to the type of progestin, compared with nonuse were as follows: norethindrone, 2.2 (95% confidence interval, 1.5–3.2) and 2.3 (1.3–3.9); levonorgestrel, 1.7 (1.4–2.0) and 2.0 (1.6–2.5); norgestimate, 1.5 (1.2-1.9) and 1.3 (0.9–1.9); desogestrel, 2.2 (1.8–2.7) and 2.1 (1.5–2.8); gestodene, 1.8 (1.6–2.0) and 1.9 (1.6–2.3); and drospirenone, 1.6 (1.2–2.2) and 1.7 (1.0–2.6), respectively. At a reduced dose of ethinyl estradiol (20 μg), the RRs for thrombotic stroke or myocardial infarction were as follows: desogestrel, 1.5 (1.3–1.9) and 1.6 (1.1–2.1); gestodene, 1.7 (1.4–2.1) and 1.2 (0.8–1.9); and drospirenone, 0.9 (0.2–3.5) and 0.0. The corresponding RRs among women who used contraceptive patches were 3.2 (0.8–12.6) and 0.0; RRs for use of a vaginal ring were 2.5 (1.4–4.4) and 2.1 (0.7–6.5). These findings show that the absolute risks of thrombotic stroke and myocardial infarction associated with the use of hormonal contraception are low, but the risk increases by a factor of 0.9 to 1.7 with use of oral contraceptives including ethinyl estradiol at a low dose (20 μg) and by a factor of 1.3 to 2.3 with those including ethinyl estradiol at a higher dose (30–40 μg), with only small differences in risk according to progestin type.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.ogx.0000422965.64164.ac

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 292

Metadata

Authors
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N.
Venue
Obstetrical & Gynecological Survey
Published
2012-10
Volume
67
Issue
10
Pages
640-641
ISSN
0029-7828 (ISSN-L)
OpenAlex
W2325527069
Cited by
292
References
0
FWCI
38.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Thrombotic Stroke and Myocardial Infarction With Hormonal Contraception. https://app.cochat.ai/papers/10.1097/01.ogx.0000422965.64164.ac
The paper
Lidegaard, Ø., Løkkegaard, E., Jensen, A., Skovlund, C. W., & Keiding, N. (2012). Thrombotic Stroke and Myocardial Infarction With Hormonal Contraception. Obstetrical & Gynecological Survey. https://doi.org/10.1097/01.ogx.0000422965.64164.ac

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.